drugset / Trial / NCT00761644
Doxil, Bevacizumab and Temsirolimus Trial
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and effectiveness of this combination of drugs will also be studied.
Timeline
- Start
- 2008-08-21
- Primary completion
- 2019-03-28
- Completion
- 2019-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | Temsirolimus | Small molecule | 12.5 mg | Intravenous |
Indications
No indication recorded.